- Faron Pharmaceuticals narrowed annual pre-tax losses on lower research and development costs.

For the year ended 31 December 2019, pre-tax losses narrowed to €13.3m from €20.1m on-year.

The R&D costs decreased by €6.3m from €16.5m in 2018 to €10.2m in 2019, with the costs of outsourced clinical trial services falling by €3.4m from €5.3 to €1.9m. The cost of materials and services used in the R&D was reduced by €1.7m from €7.3 to €5.6m.

At 9:50am: [LON:FARN] Faron Pharmaceuticals share price was +60p at 440p

Story provided by